Matthew Henn, PhD

Cambridge, Massachusetts, United States
Matthew Henn is Executive Vice President and Chief Scientific Officer at Seres Therapeutics. He has been involved in the discovery and development of multiple microbiome therapeutics across infectious, inflammatory, and oncology indications. He has authored over 70 peer-reviewed publications; his research has focused on microbial populations and the functional role of microbes in both environmental and human disease applications, and also the development of genomic and functional tools to study these populations. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for the National Institutes of Health’s Viral Pathogen Bioinformatics Resource Center, as an ad-hoc reviewer and editor of various peer-reviewed journals, and as a scientific advisor to non-profit and for-profit organizations. He currently serves on the Board of Directors of the Microbiome Therapeutics Innovation Group and the scientific advisory board of Growcentia, Inc, an agricultural microbiome company. Dr. Henn is formally trained in ecology and evolutionary biology and earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in Microbiology at Duke University.
Speaking In
12:15 PM - 1:30 PM (PDT)
Wednesday, June 15
As of March 31, 2022, reports 1,485 ongoing clinical studies related to the…